Group sues to get approval for Provenge

07/31/2007 | Bloomberg Businessweek

A group of prostate cancer patients and Dendreon Corp. investors sued FDA officials involved in the agency's refusal to approve Provenge, a prostate cancer vaccine. The lawsuit, prompted by an unexpected disapproval in May after an FDA panel backed the drug, seeks to enjoin the agency from denying marketing approval for the drug.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Chief, Product Review Branch
FDA/Center for Biologics Evaluation and Research
Silver Spring, MD
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ